PREDICTIVE TECHNOLOGY GROUP APPOINTS DR. GREGORY A. PRINCE TO ITS SCIENTIFIC ADVISORY BOARD

Salt Lake City, UT — January 17, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments, announces that Dr. Gregory A. Prince will join PRED’s Scientific Advisory Board.  As a co-founder and CEO of Virion Systems, Inc., Dr. Prince brings pharmaceutical research and development and commercialization expertise to the Scientific Advisory Board team.

After earning doctorate degrees at UCLA (DDS, 1973; PhD, 1975) and serving a post-doctoral fellowship at the National Institutes of Health, Dr. Prince spent four decades in virology research, with a focus on the respiratory syncytial virus (RSV). He pioneered the prevention of RSV disease in high-risk infants, and as co-founder and CEO of Virion Systems, Inc. worked with MedImmune (acquired by AstraZeneca in 2007) to develop Synagis®. AstraZeneca markets Synagis within the United States, while AbbVie markets Synagis in all other regions.

“I welcome Greg to the PRED team.  His vision and experience in applying data analytics for disease identification and understanding of the individual will help ensure each and every patient receives the most appropriate therapy at the earliest possible point of intervention,” said Bradley Robinson, CEO, Predictive Technology Group, Inc. “Dr. Prince has already contributed greatly to society and the health of newborns, he is passionate about applying his career knowledge to improve quality of life in other population groups.”

Dixie State University-St. George, Utah inducted Dr. Prince to its Hall of Fame in 1999, in recognition of his scientific achievements, and later in 2012, the university granted him an honorary Doctorate of Humanities.  Dr. Prince serves on the national advisory councils at four universities, and as the governor of Wesley Theological Seminary in Washington, D.C. He holds adjunct professorships at UCLA and Dixie State University and currently serves as Chief Scientific Officer at Soft Cell Biological Research, LLC.

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis.

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED continues to explore the possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP (PRED) APPOINTS JOHN C. NELSON, M.D., M.P.H. TO THE PREDICTIVE TECHNOLOGY GROUP SCIENTIFIC ADVISORY BOARD

Salt Lake City, UT — January 11, 2018 — Predictive Technology Group, Inc. (OTCPINK: PRED) announces that Dr. John C. Nelson, M.D., M.P.H. will join the Predictive Technology Group Scientific Advisory Board.  Dr. Nelson an obstetrician and gynecologist from Salt Lake City, Utah, brings a wealth of experience to PRED. Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine.

Dr. Nelson served as President of the American Medical Association, Salt Lake County Medical Society and, the Utah Medical Association.  Also, he chaired the Finance and Planning Committee of the World Medical Association. He served on the Advisory Committee to the Director of the National Institutes of Health (NIH), as well as, on the advisory committee for the Agency for Healthcare Research and Quality (AHRQ).  As a spokesperson for the American Medical Association Alliance, he lectured on detecting and preventing interpersonal violence. Dr. Nelson became a charter member of the Prospective Payment Assessment Commission (ProPAC), now known as MedPAC.

Dr. Nelson received numerous awards, among which are the Alumnus of the Year at Utah State University, the Distinguished Service Award from the University of Utah School of Medicine, the Emeritus Merit of Honor Award from the University of Utah Alumni Association, and the Light of Learning Award from the Utah Department of Education.  As a founding co-chair of the Commission to End Healthcare Disparities, Dr. Nelson received a Lifetime Service Award from the National Medical Association.

Dr. Nelson’s civic involvement includes time on the advisory committee of the local Boys and Girls Club of Salt Lake City, the Christmas Box House board, and the board of Operation Kids.

As PRED continues to advance its growth, Dr. Nelson’s vast medical, scientific, and business knowledge and experience brings a valued addition to the Company’s advisory team.

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED continues to explore the possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

 

PREDICTIVE TECHNOLOGY GROUP FINALIZES LETTER OF INTENT TO ACQUIRE FLAGSHIPHEALTH GROUP

Salt Lake City, UT — January 9, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments, announces that it finalized an arrangement for the acquisition of FlagshipHealth Group, a Minneapolis-based provider of sales and consulting services for the healthcare industry.

The business combination provides essential resources for Predictive Technology Group to develop, launch, and grow its services directed at limiting disease and improving the health and well-being of individuals confronting a wide-range of medical conditions. Since February 2017, Flagship provided sales and marketing support for the successful launch of treatments offered by Predictive Technology Group’s wholly owned subsidiary Predictive Biotech one of the fastest growing regenerative medicine portfolios in the U.S.

FlagshipHealth Group also worked with Predictive Technology Group’s wholly owned subsidiary Predictive Therapeutics toward commercialization, in late 2018, of the ARTGuide™, a genetic diagnostic for endometriosis and other concerns addressed in fertility clinics, and FertilityDx™ Services, a test suite delivering personalized and comprehensive genetic diagnostic services to couples undergoing infertility care.

The seasoned and proven management team at FlagshipHealth Group brings diverse and deep experience in all areas of healthcare. The company focuses on delivering innovative and beneficial health and treatment approaches to people who can benefit from them, and in ways which help improve the services and efficiency of those providing care. FlagshipHealth Group, headed by President and Founder Tim Lacy, a veteran executive whose experience includes senior executive positions at UnitedHealth Group and Walgreens, and FlagshipHealth’s Michael Herbert, a seasoned healthcare veteran who has focused on the Predictive partnership since February of 2017. Also, William W. McGuire, M.D., the former Chairman and Chief Executive Officer of UnitedHealth Group for 17 years in its formative development and growth phase, provides Predictive Technology Group with strategic and tactical planning around healthcare issues and customer needs.

“We are very pleased to have the team at Flagship join the Predictive organization,” said Bradley Robinson, CEO of Predictive Technology Group. “As we move forward to fully address important challenges, such as endometriosis, and our efforts in regenerative health interventions, the team at Flagship demonstrates a tremendous understanding of the complexity and stakeholder diversity within healthcare delivery, finance and administration. With the expansion of our products and services addressing significant medical problems confronting individuals and families throughout the world and our imminent commercialization of diagnostics and therapeutics for endometriosis, it became obvious that the integration of our two organizations better serves patients, care providers, and shareholders.”

Commenting on the opportunities, Tim Lacy said, “We have enjoyed working closely with Predictive since our introduction in 2010, and through Predictive Biotech’s regenerative medicine commercialization in 2017.  We are excited to transition Flagship from a long-time advisory partner into a permanent contributor to the Predictive family.”

“Predictive’s business success will be directly linked to enhancing the well-being of the people it serves and its ability to improve the system within which it operates to address specific health challenges. This will be particularly true in association with the pending launch of products and services directed at the immense problems surrounding endometriosis, women’s health and the supporting health care delivery system – whether measured in terms of economic cost, patient morbidity, the needs of care providers or system efficiency,” said Dr. McGuire. “There is great potential in Predictive’s ability to positively influence an area of women’s health that has been largely underserved.”

In conjunction with significant additions to business management and its advisory group, the combined resources of FlagshipHealth Group, Predictive Technology Group and its subsidiaries, will be immediately directed at continued expansion of the regenerative medicine business and its efforts to assist women in overcoming the devastating consequences of endometriosis, including appropriate early-stage diagnosis and subsequent treatment.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.

 

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP APPOINTS DR. HUGH S. TAYLOR, M.D. TO THE PREDICTIVE TECHNOLOGY GROUP’S SCIENTIFIC ADVISORY BOARD

Salt Lake City, UT — January 4, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED) announces that Dr. Hugh S. Taylor, M.D., joined the Predictive Technology Group’s Scientific Advisory Board. Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine. Dr. Taylor, a Chief of Obstetrics and Gynecology at Yale University, brings extensive clinical research and development expertise in endometriosis and women’s health to PRED’s Scientific Advisory Board team.

Dr. Taylor’s many accomplishments include Anita O’Keeffe Young Professor and Chairs Department of Obstetrics Gynecology and Reproductive Sciences at Yale School of Medicine and Chief of Obstetrics, and Gynecology at Yale-New Haven Hospital. He teaches as Professor of Molecular, Cellular and Developmental Biology at Yale University. His clinical interests include endometriosis, infertility, implantation, Asherman’s syndrome, menopause and uterine anomalies.

Also, Dr. Taylor, a board-certified specialist in Obstetrics and Gynecology and in Reproductive Endocrinology, received eight National Institutes of Health research grants. Dr. Taylor published more than 300 articles in leading medical journals, continues as the Editor-In-Chief of Reproductive Sciences, and elected to the membership of the National Academy of Medicine.

Dr. Taylor received his undergraduate training at Yale University and his medical degree from the University Of Connecticut School Of Medicine. He completed his residency in obstetrics and gynecology at Yale. His postdoctoral training included a fellowship in reproductive endocrinology and infertility, as well as, a fellowship in molecular biology, both at Yale.

Predictive plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis.

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

 

PREDICTIVE TECHNOLOGY GROUP APPOINTS DR. MICHAEL DEY TO BOARD OF DIRECTORS

CEO of Predictive Therapeutics and Former Wyeth Women’s Health Executive Joins Predictive Technology Group Board of Directors

Salt Lake City, UT — January 2, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED), announces the appointment of Michael Dey, Ph.D. to the Board of Directors of Predictive Technology Group, Inc.  Dr. Dey will assist in corporate governance and guide the development and commercialization of technology and products in all PRED subsidiaries.

In addition to serving as a PRED Board Member, Dr. Dey will continue as Chief Executive Officer of Predicitive Therapeutics, Inc., a wholly owned subsidiary of PRED.  Before joining PRED, Dr. Dey had executive positions at Wyeth, later acquired by Pfizer, where he was both the President and the President of Scientific Affairs division for Wyeth’s Women’s Health Care business.  As President of Wyeth’s Women’s Health Care business for seven years, Dr. Dey managed its global resources of more than $3 billion annually.

“We are very pleased to have Mike join PRED’s Board of Directors,” said Bradley Robinson, CEO of PRED. “Mike’s breadth of knowledge and experience in life sciences will greatly assist in advancing science and technology and bringing related diagnostics and therapeutics to the clinic to improve the care and outcomes of patients.”

Before his leadership role in women’s health care, Dr. Dey served as Vice President, General Manager of ESI Pharma, Inc. In 1995, with Wyeth’s acquisition of American Cyanamid and Lederle Standard Products, Dr. Dey became President of ESI Lederle, Inc.  As President of ESI Lederle, Dr. Dey’s responsibilities included directing one of the largest generic companies in the U.S. with more than $500 million in sales, approximately 150 people in R&D and 100 people in marketing and sales. ESI Lederle sold both oral and injectable products that included Tubex®, the prefilled syringe delivery system.

Dr. Dey received an undergraduate degree in Biology/Chemistry in 1973, a Master’s Degree in 1980 in Pharmacology and Toxicology and a Ph.D. in 1984 in Pharmacology and Toxicology.

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the treatment of endometriosis. Dr. Dey’s appointment will assist PRED to reach these commercial milestones effectively.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Predictive Technology Group, Inc. (PRED) Announces Issuance of U.S. Patent for Method of Treating Endometriosis

Issuance Strengthens Commercialization Strategy of Company’s Gene-Based Endometriosis Diagnostics and Therapeutics

Salt Lake City, UT – December 28, 2017- Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, announced today the issuance of U.S. patent 9,840,738 directed to treating patients genetically predisposed to endometriosis.

Endometriosis, a common gynecologic disorder estimated to affect 1 in 10 women in their reproductive years – equates to approximately 176 million women in the world.  U.S. patent 9,840,738, builds on the coverage provided by previously issued US patent 8,932,993

“This technology brings a significant opportunity for PRED and to the healthcare market, assisting women and their physicians in designing a course of care that places women on the most appropriate therapy at the earliest possible stage of disease progression,” said Bradley Robinson, President and Chief Executive Officer of PRED. “The rights to this technology are seen as a synergistic companion to the therapeutic products PRED intends to bring to market.”

Bradley Robinson described the claims of U.S. patent 9,840,738 as covering any treatment of endometriosis in women, whether symptomatic or not, having any one (or more) of approximately 1,400 endometriosis-associated genetic markers.

About Predictive Technology Group, Inc. 

Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding Company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com. 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

 

 

PREDICTIVE TECHNOLOGY GROUP APPOINTS JOHN E. SORRENTINO TO CHAIR PREDICTIVE THERAPEUTICS’ SCIENTIFIC ADVISORY BOARD

PREDICTIVE TECHNOLOGY GROUP APPOINTS JOHN E. SORRENTINO TO CHAIR PREDICTIVE THERAPEUTICS’ SCIENTIFIC ADVISORY BOARD

Salt Lake City, UT — December 26, 2017 — Predictive Technology Group, Inc. (OTC PINK: PRED) announces that John E. Sorrentino, will chair the Predictive Therapeutics’ Scientific Advisory Board. Predictive Therapeutics, a wholly owned subsidiary of Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine. Sorrentino is Vice President and Chief Operating Officer of Vaccine Research and Development at Pfizer and brings his vast experience in R&D and clinical laboratory management to the Predictive Therapeutics’ Advisory team.

Sorrentino has over 35 years of senior management experience in the life sciences. Focused on improving public health, he has held leadership roles in private, and public companies, as well as government and non-profit institutions. Prior to joining Wyeth, later acquired by Pfizer, 14 years ago, Sorrentino held executive positions in several organizations that provided neonatal screening and related clinical services.  Sorrentino’s expertise has had him appear before state legislators, the US Congress and professional societies on a variety of healthcare and policy issues.

“We are very pleased to have John head up our Scientific Advisory Board,” said Dr. Mike Dey, CEO of Predictive Therapeutics and former Wyeth colleague. “John’s experience in clinical testing and women’s health will be an invaluable addition to our current team of experts and our mission to effectively treat endometriosis.”

“I am excited to chair the Predictive Therapeutics’ Scientific Advisory Board,” said John Sorrentino. “The work they are doing in genetic testing has potential to ultimately assist mothers and their children in knowing if they need therapeutic treatment and could improve health outcomes.”

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Northstar Electronics, Inc. (NEIK) Progress Update on Deal With Major Aerospace Manufacturer

Vancouver, British Columbia-October 25, 2017 – Northstar Electronics, Inc. (OTCQB:NEIK) previously stated that its subsidiary, Northstar Sealand Enterprises Ltd. (NSEL), is working to acquire the worldwide rights to a “Turbo-Prop” single engine industrial airplane from a world leader in the aerospace industry.  The timeline for the final agreement with the subsidiary company that owns the rights to the airplane has been extended. The main reason is that there is a strong possibility that the parent company will use our transaction as an “Offset,” which means that much of our acquisition costs included the Intellectual Property (IP), prototype, tooling, etc. would be covered (when international companies win large multi-billion contracts from the Canadian government, the companies have obligations to put considerable work into local companies.)

As mentioned before, the primary applications for the airplane are in “Agriculture and Rapid Response Forest Fire Fighting” where the needs for both types of airplanes are high. NSEL is continuing its assessment of the “Cloud Seeding” market. So far, the results look positive. Management believes the new design features of the NSEL airplane will quickly lead to it being a leader in its class.

Once the airplane “Rights Acquisition Agreement” is signed, NSEL intends to aggressively roll out its plans to initiate the actions leading to manufacturing the airplane and marketing it worldwide. The Company`s basic marketing strategy is to first focus on markets in which the former version of the plane was a big success, with many of those customers expressing considerable interest in the new, innovated version.  NSEL plans to then expand outwards to other markets, domestic and foreign, where there are also strong needs for the performance capabilities of this new design.

NSEL’s estimates for annual revenues in the fifth year of operations are of the order of $30M, with good profit margins.

On another note, Northstar is pleased to report that a former senior executive at the world’s largest defense and aerospace company has become an advisor to the Company. He has a stellar background and brings extensive international experience to the Company.

Dr. Wilson Russell, CEO of Northstar Electronics, comments, “Although the timeline to an agreement has been extended, the potential resulting benefits are highly significant to Northstar. It also means that we would likely have the support of the parent company for up to five years going forward. ”

Currently, Northstar wishes to raise funds. The instrument is comprised of a common share plus a warrant. Northstar is looking for investors who would like to be part of what we believe is an attractive opportunity in the growing Aerospace industry. Interested parties can contact Wilson Russell, CEO, at wrussell@northstarelectronics.com.

For further information about this news release contact, Rich Kaiser, Investor Relations, Yes International, 757-306-6090, yes@yesinternational.com.

About Northstar Electronics, Inc.

Northstar Electronics, Inc. (OTCQB:NEIK) established in the late 1990’s carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers. Since termination of the above contracts, Northstar has moved towards making and selling its own independent systems, www.northstarelectronics.com.

Safe Harbor Statement:
This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.

DOYEN ELEMENTS INC.’S Stock Subscription Offering Now OPEN

September 12, 2017

Dear Investors,

DOYEN ELEMENT, INC. can now sell to both accredited and non-accredited investors shares of its stock, offering Seven Million (7M) shares at Seven US Dollars ($7.00) per share under the effective registration.

Please use promo code YES INTL in the section of the offering agreement upon submitting your subscription agreement; http://www.doyenelements.com/invest/ provides the necessary information to proceed forward with the stock subscription offering in becoming a shareholder in DOYEN.

DOYEN’s unique and novel business model provides ALL services as they pertain to the medical cannabis industry everything from building space to distribution. The Company is NOT directly involved in the actual growing of cannabis but provides a turn-key solution to producers. These solutions enable the Company to generate revenues and to grow its footprint in the medical cannabis space in Colorado, USA.

If you have any questions on the sale of shares registered under the Regulation A, Tier II offering, please contact us with any and all questions, regarding this 7M at $7.00 per share offering, rich@yesinternational.com, 757-306-6090.

With Warmest Regards,

/s/

Rich Kaiser
Investor Relations- DOYEN ELEMENTS, INC.
www.doyenelements.com
rich@yesinternational.com
757-306-6090

Disclaimer: An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that Doyen Elements, Inc. may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a copy of the offering circular that is part of that offering statement here. You should read the offering circular before making any investment.

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) EVALUATES UP-LISTING TRADING STATUS TO OTCQB

Salt Lake City, UT- September 11, 2017- Predictive Technology Group, Inc. (OTCPINK: PRED) proceeds with the evaluation of moving the Company’s trading status to OTCQB on OTC MARKETS.

Management determined the “NEW” Alternative Listing Standards which became available to issuers could be prudent, saving time and cost effective objective to uplift PRED’s tradable shares.

Effective May 18, 2017, the OTC Markets amended its rules for the OTCQB qualification which allows the issuers that follow “Alternative Reporting Standard.”  The new standard for OTCQB for alternative reporters now allows a company to file 1-year audited financial reports.  These reports are to US GAAP standards through a PCAOB qualified auditor.   A company must still maintain a bid price of $0.01 per shares, needs a board of directors with at least two independent directors, and an audit committee comprised of a majority of independent directors.

OTC MARKETS believes these updated rules for OTCQB provides non-SEC Reporting companies with the benefits of public trading while lowering the cost and complexity of being public. The new market standards give “Alternative Reporting” companies an efficient way to raise their profile among the investor and broker dealer communities, access greater liquidity, and trade on a SEC-recognized market. Thus, removing the trading restrictions placed on “Pink” market securities.

Based on these news standards, PRED’s management remains confident that uplifting to the OTCQB can be done timely. Once management and the board at PRED finish their due diligence on OTC MARKETS’ “ALTERNATIVE REPORTING STANDARDS,” expect more news to follow.

Management continues on its fiduciary path with a primary objective of creating shareholder value.

About Predictive Technology Group, Inc.:

Predictive Technology Group, Inc. (OTCPINK:PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products effectively designed to prevent and treat diseases.

For further information about PRED and this release contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com, www.predictivetechnologygroup.com.

 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

 

Contact

Rich Kaiser

YES INTERNATIONAL

757-306-6090

yes@yesinternational.com

www.predictivetechnologygroup.com

www.predbiotech.com

www.predrx.com